Nuvalent Submits Neladalkib NDA, Meeting Key 1H 2026 Timeline but Awaiting FDA Acceptance

What happened

Nuvalent announced on April 7, 2026, that it submitted a New Drug Application to the FDA for neladalkib in TKI pre-treated ALK-positive NSCLC, based on data from the ALKOVE-1 Phase 1/2 trial. This submission aligns precisely with management's guidance for a 1H 2026 filing, a critical milestone highlighted in the DeepValue report as a de-risking event for the investment thesis. The report had emphasized that timely submission by June 30, 2026, would support the base case valuation of $105, while delays could trigger downside toward $70. With this step completed, operational execution is validated, but investors must now watch for FDA acceptance, which involves reviewing CMC modules and safety data. The submission reduces near-term binary risk but does not alter the broader regulatory and commercial uncertainties, including zidesamtinib's September 2026 PDUFA date and revenue-sharing obligations.

Implication

Investors should view this submission as a positive but incremental step, as it meets management's timeline but does not guarantee FDA acceptance or approval. The next critical checkpoint is formal FDA acceptance, which could involve scrutiny of manufacturing and safety data, with any delays risking valuation compression toward the bear case of $70. If accepted, neladalkib joins zidesamtinib in the regulatory pipeline, potentially supporting a move toward the base case implied value of $105, but this remains contingent on clean reviews and controlled burn. However, elevated cash burn and revenue-sharing obligations continue to limit upside, and the crowded, event-driven market sentiment suggests potential volatility around further announcements. Therefore, maintaining a cautious stance is prudent until acceptance is confirmed and the zidesamtinib review progresses without hiccups.

Thesis delta

The thesis shifts from anticipating the NDA submission to focusing on FDA acceptance as the next de-risking step, confirming part of the base scenario but not altering the overall WAIT rating. This reduces execution risk but does not change the valuation sensitivity to regulatory outcomes, such as potential review delays or commercial hurdles. Investors should now monitor for acceptance timing and any FDA signals, while remaining aware that the investment case still hinges on binary approvals and post-launch economics.